Novartis Raises Mid-Term Growth Forecast After Restructuring
Novartis AG raised its mid-term sales growth forecast as the Swiss drugmaker narrows its focus on innovative medicines
2023-11-28 16:15
Novartis Makes $3.5 Billion Bet on Chinook’s Rare Disease Drugs
Novartis AG agreed to buy Chinook Therapeutics Inc. for as much as $3.5 billion to add two promising
2023-06-12 15:59
Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma
2023-05-17 16:20